Older patients with acute myeloid leukemia are more likely to exhibit intrinsic disease resistance as well as poor tolerance to therapy and treatment-related mortality. Identifying older patients that may benefit from RIC HSCT requires a thorough review of the scientific literature, assessment of patient populations studied, regimens used, and outcomes achieved. Although some patients benefit greatly from this procedure, few are currently referred for evaluation. This educational program will review the most current, effective treatment strategies for older patients with AML with a focus on optimizing patient selection and supportive care strategies.

Learning Objectives

At the end of this educational activity, participants should be able to:

    Acute myeloid leukemia induction:

  • Explain the relative importance of age, performance status, comorbidity, organ dysfunction, cytogenetics, and molecular markers as predictive factors in selecting patients with AML for induction therapy.
  • Assimilate patient population and outcomes from clinical trials evaluating newer therapies for older patients with AML and apply data to optimize therapy for older patients with AML.
  • Implement a state-of-the-art supportive care regimen to prevent bacterial and fungal infections in patients with AML.
  • Acute myeloid leukemia Transplant:

  • Synthesize the published entry criteria and results for RIC transplant into a coherent and clinically applicable guide to evaluate older patients for eligibility for allogeneic transplant.
  • Explain the impact of patient and disease specific factors that influence allogeneic transplant outcomes. /li>
  • Differentiate outcomes achieved among RIC regimens evaluated for older patients with AML.
  • Assimilate and apply patient population and outcomes data to optimize RIC regimen selection for eligible older patients with AML.
  • Demonstrate the ability to apply current evidence to the post-transplant management of older patients with AML receiving RIC HSCT.
  • Identify strategies to optimize graft-versus-leukemia effect in RIC for AML.


  • Clinical Director, Leukemia Program, Hematology, Massachusetts General Hospital
    Associate Professor of Medicine, Harvard Medical School
  • Director, Bone Marrow Transplant Program, MGH
    Chief, Walter Bauer Firm, Hematology/Oncology Unit, MGH
    Professor of Medicine, Hematology/Oncology, Harvard Medical School

CME Information



This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education. This activity has expired. CME/CE Released: 2/17/2011; Valid for credit through 2/17/2012.  

Credit Designation

Even though this event is no longer accredited, providing information regarding planning, disclosure, and conflict of interest is important to us. This activity was accredited by the Elsevier Office of Continuing Medical Education (EOCME). Please see the original CME information below:

Resolution of Conflict of Interest

The EOCME has implemented a process to resolve conflict of interest for each CME activity. In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, the EOCME has resolved the conflict by external content review.

Unapproved/Off-Label Use Disclosure
The EOCME requires CME faculty to disclose to the participants:
1. When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of FDA-approved labeling. This information is intended solely for CME and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.


Our evidence-based curriculum is supported by an educational grant from Otsuka America Pharmaceutical, Inc.


The following planners of this activity have indicated that neither they nor their families have a significant financial interest or affiliation with the manufacturer of any commercial products or provider of commercial services:

Robert J. Birnbaum, MD, PhD: Planner 

John A. Fromson, MD: Planner, reviewer 

Anan Nathif, EdM: Planner 

Tristan Gorrindo, MD: Planner 

Timothy Lynch: Planner 

Sandy Breslow, Elsevier Office of CME: Planner

Mary Ellen Shepard, PhD: Planner



The following speakers of this activity have indicated that neither they nor their spouse/partner have a relevant financial relationship to disclose:



Thomas Spitzer, MD

Karen Ballen, MD


Hardware/Software Specifications: 

This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration: 
Flash Player: Adobe Flash Player 10.1+ 
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+ 
Operating System: Windows XP+ or Mac OS X 10.4+ 
Internet Connection: 1 Mbps or higher

Minimum Requirements: 
Windows PC:
500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera 
Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit





This program has received support in the form of educational grants from the following companies: